CIPLA MEDPRO REGISTERS TRIOMUNE IN SOUTH AFRICA

Indian generic drug firm Cipla Medpro has registered the antiretroviral drug Triomune in South Africa, the company announced. Triomune contains lamivudine, nevirapine and stavudine -- all part of first-line antiretroviral treatment.

The drug, which will be supplied through local company Enaleni Pharmaceuticals, can help reduce the pill-intake for HIV-positive patients from the current regimen -- six or more tablets per day -- to two tablets per day.

The agreement "is indeed a breakthrough, and represents Cipla's commitment to making life-prolonging medicines accessible and affordable to the broader population," noted Trevor Edwards, CEO of Enaleni Pharmaceuticals.